Cyclosporine: what clinicians need to know
- PMID: 8785893
Cyclosporine: what clinicians need to know
Abstract
Cyclosporine is known to be highly efficacious for the treatment of psoriasis as well as several other dermatologic conditions. Because of its profound anti-inflammatory properties and a side-effect profile that differs from other agents, such as methotrexate, the availability of cyclosporine confers certain advantages in meeting the challenges of treating recalcitrant psoriasis. In short-term use, cyclosporine can induce dramatic improvements in psoriasis, especially patients who present with intense inflammation. Because of nephrotoxicity and the possible development of hypertension, however, its utility in long-term usage, especially continuous usage beyond 1 year, is still to be defined. With contemporary attempts to use combination and rotational therapies to maximize therapeutic efficacy and minimize risk of long-term side effects, cyclosporine is definitely a welcome addition to our current armamentarium in the treatment of psoriasis.
Similar articles
-
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.J Am Acad Dermatol. 2001 Apr;44(4):643-51. doi: 10.1067/mjd.2001.112400. J Am Acad Dermatol. 2001. PMID: 11260540 Clinical Trial.
-
Biologics in combination with nonbiologics: efficacy and safety.Dermatol Ther. 2004;17(5):432-40. doi: 10.1111/j.1396-0296.2004.04046.x. Dermatol Ther. 2004. PMID: 15379778 Review.
-
Long-term safety of cyclosporine in the treatment of psoriasis.Arch Dermatol. 1996 Jun;132(6):623-9. Arch Dermatol. 1996. PMID: 8651712 Clinical Trial.
-
[Cyclosporine in the treatment of psoriasis].Tidsskr Nor Laegeforen. 1992 Sep 20;112(22):2863-5. Tidsskr Nor Laegeforen. 1992. PMID: 1412327 Norwegian.
-
Treatment of psoriasis. Part 2. Systemic therapies.J Am Acad Dermatol. 2001 Nov;45(5):649-61; quiz 662-4. doi: 10.1067/mjd.2001.117047. J Am Acad Dermatol. 2001. PMID: 11606913 Review.
Cited by
-
Recognition and treatment of psoriasis. Special considerations in elderly patients.Drugs Aging. 1998 Mar;12(3):177-90. doi: 10.2165/00002512-199812030-00002. Drugs Aging. 1998. PMID: 9534019 Review.
-
In vitro pharmacokinetics of anti-psoriatic fumaric acid esters.BMC Pharmacol. 2004 Oct 12;4:22. doi: 10.1186/1471-2210-4-22. BMC Pharmacol. 2004. PMID: 15479475 Free PMC article.
-
Comparative tolerability of systemic treatments for plaque-type psoriasis.Drug Saf. 2002;25(13):913-27. doi: 10.2165/00002018-200225130-00003. Drug Saf. 2002. PMID: 12381213 Review.
-
Pharmacokinetics of oral fumarates in healthy subjects.Br J Clin Pharmacol. 2004 Oct;58(4):429-32. doi: 10.1111/j.1365-2125.2004.02145.x. Br J Clin Pharmacol. 2004. PMID: 15373936 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical